文献速递脊柱关节炎其他结缔组织病

乌司奴单抗治疗中重度斑块状银屑病可消退亚临床附着点炎

Regression of Peripheral Subclinical Enthesopathy in Therapy-Naive Patients Treated With Ustekinumab for Moderate-to-Severe Chronic Plaque Psoriasis: A Fifty-Two-Week, Prospective, Open-Label Feasibility Study.
PubMed 文献 · Arthritis Rheumatol · 2019-03-04

一项52周前瞻性开放标签可行性研究显示,未接受系统治疗且无银屑病关节炎症状的中重度银屑病患者中,49.3%存在至少1处炎症性附着点异常;乌司奴单抗治疗24周和42周时炎症评分分别较基线下降42.2%和47.5%,而结构异常无显著变化。

要点

  • 中重度银屑病患者中亚临床附着点炎常见,超声筛查可发现约半数患者存在炎症性异常。
  • 乌司奴单抗治疗24周内可显著降低超声炎症评分,并维持至52周。
  • 附着点结构异常在52周治疗期间未见显著改善。

核心结论

  • 白细胞介素12/23抑制可在12周内抑制银屑病患者的亚临床附着点炎,并维持至52周。

研究设计与样本

  • 其中23例超声显示炎症性附着点异常的患者接受乌司奴单抗治疗52周,于第0、12、24、52周评估附着点超声改变。

主要发现

  • 筛查的银屑病患者中49.3%存在至少1处炎症性附着点异常。
  • 银屑病患者平均炎症评分高于健康志愿者(9.9±6.6 vs 1.0±1.4)。
  • 治疗第0周至第24周平均炎症评分显著下降42.2%(-4.2,95%CI -6.3~-2.1;P<0.001)。
  • 至第42周平均炎症评分下降47.5%(-4.7,95%CI -7.1~-2.3;P=0.001)。
  • 附着点结构异常在治疗期间无显著变化。

关键数值与推荐

  • 每个灰度或能量多普勒超声参数评分>0定义为异常,并基于Glasgow超声附着点炎评分系统计算总和评分。

临床怎么用

  • 对中重度银屑病患者可考虑超声筛查亚临床附着点炎,乌司奴单抗治疗可能抑制炎症性附着点病变。
  • 治疗决策仍需结合皮肤病情,亚临床附着点炎的长期意义需进一步研究。

局限性

  • 开放标签、无对照、样本量小(23例治疗患者),为可行性研究。
  • 随访至52周,不能确定治疗是否可预防PsA发生。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To investigate whether sonographically determined subclinical enthesopathy in patients with moderate-to-severe psoriasis regresses with the use of ustekinumab therapy for skin disease. METHODS: Seventy-three patients with moderate-to-severe psoriasis, who were not treated with systemic therapy and did not have symptoms of psoriatic arthritis (PsA), and 23 healthy volunteers were screened by ultrasound for subclinical enthesitis. Subsequently, 23 patients with psoriasis whose ultrasound results showed inflammatory changes were treated with ustekinumab for 52 weeks. The evolution of sonographic abnormalities of the upper and lower limb entheses was assessed using an extensive gray-scale and power Doppler (PD) ultrasound protocol at weeks 0, 12, 24, and 52. For each parameter, a gray-scale or PD ultrasound score of >0 was determined to be abnormal, and a summative score based on the Glasgow Ultrasound Enthesitis Scoring System was calculated. RESULTS: Of all the patients with psoriasis screened using ultrasound, 49.3% had at least 1 inflammatory entheseal abnormality. Mean ± SD inflammation scores were higher in the patients with psoriasis compared with the healthy volunteers (9.9 ± 6.6 versus 1.0 ± 1.4). With treatment, the mean inflammation scores decreased significantly by 42.2% from week 0 to week 24 (-4.2 [95% confidence interval -6.3, -2.1]; P < 0.001) and by 47.5% by week 42 (-4.7 [95% confidence interval -7.1, -2.3]; P = 0.001). Entheseal structural abnormalities did not change significantly during treatment. CONCLUSION: Within 12 weeks of treatment, interleukin-12 (IL-12)/IL-23 inhibition for psoriasis appears to suppress subclinical enthesopathy, and the suppression is maintained through week 52. Further longitudinal studies are needed to determine whether therapy initiated for skin disease may prevent the development of PsA.

来源:Arthritis Rheumatol,查看原文。版权归原作者所有。

引用

  1. Savage L, Goodfield M, Horton L, et al. Regression of Peripheral Subclinical Enthesopathy in Therapy-Naive Patients Treated With Ustekinumab for Moderate-to-Severe Chronic Plaque Psoriasis: A Fifty-Two-Week, Prospective, Open-Label Feasibility Study. Arthritis Rheumatol. 2019. PMID: 30468001. doi:10.1002/art.40778

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。